E-Mail
IMAGE: INRS Professor Charles Ramassamy, specialist on Alzheimer s disease, doctoral student Mohamed Raâfet Ben Khedher and postdoctoral student Mohamed Haddad. view more
Credit: INRS
A Quebec research team has discovered two early plasma markers to detect Alzheimer s disease five years before its onset. The results of this recent study led by the doctoral student Mohamed Raâfet Ben Khedher and postdoctoral student Mohamed Haddad, directed by Professor Charles Ramassamy of the Institut national de la recherche scientifique (INRS), have been published in the prestigious scientific journal
Alzheimer s & Dementia: Translational Research & Clinical Interventions (
TRCI).
The diagnosis of Alzheimer s disease is usually based on a series of psychometric tests assessing cognitive function, brain imaging and cerebrospinal fluid analysis. Yet, these tests have their limitations. The lumbar puncture is invasive, while brain imaging is expensive and not 100% reliab
Early plasma markers help track the progression of Alzheimer s disease
A Quebec research team has discovered two early plasma markers to detect Alzheimer s disease five years before its onset. The results of this recent study led by the doctoral student Mohamed Raâfet Ben Khedher and postdoctoral student Mohamed Haddad, directed by Professor Charles Ramassamy of the Institut national de la recherche scientifique (INRS), have been published in the prestigious scientific journal
Alzheimer s & Dementia: Translational Research & Clinical Interventions (
TRCI).
The diagnosis of Alzheimer s disease is usually based on a series of psychometric tests assessing cognitive function, brain imaging and cerebrospinal fluid analysis. Yet, these tests have their limitations.
E-Mail
IMAGE: Nirmal Verma, Ph.D., and several other researchers contributed to the recent study potentially linking low blood amylin levels to reduced progression of Alzheimer s disease. view more
Credit: Photo by Pete Comparoni | UKphoto
LEXINGTON, Ky. (January 20, 2021) - More than 5.7 million Americans live with Alzheimer s disease and that number is projected to triple by 2050. Despite the growing number there is not a cure. Florin Despa a professor with the University of Kentucky s department of pharmacology and nutritional sciences says, The mechanisms underlying neurodegenerative diseases are largely unknown and effective therapies are lacking. That is why numerous studies and trials are ongoing around the world including at the University of Kentucky. One of those studies by University of Kentucky researchers was recently published in
The team’s work shows that early pathological processes in the brains of individuals who are genetically predisposed to develop Alzheimer’s disease are modulated by a pancreatic hormone called amylin. This study is the first to show that the brains of patients with familial AD accumulate amyloid-forming amylin secreted by the pancreas. “Our study suggests an alternative approach to reduce the progression of Alzheimer’s disease through the modulation of blood levels of amylin. In addition, the results of this study can point to the pancreatic hormone amylin as a potential missing molecular link between metabolic disorders and increased risk for Alzheimer’s disease. Specifically, amylin dysregulation contributes to both type-2 diabetes and Alzheimer’s disease.”
Share or Print this page
In aggressive pursuit of its vision of a world without Alzheimer’s and all other dementia, the Association once again made its
largest-ever research investment in FY20,
granting more than $47 million to 139 new scientific investigations. Investments included awards to 119 projects funded through the
International Research Grant Program, representing proposals ranked highest by a peer-reviewed process in a highly competitive field of 406 applications submitted from 865 letters of intent. As the world’s leading nonprofit funder of Alzheimer’s and dementia research, the Association is currently investing $208 million in more than 590 active best-of-field projects in 31 countries.
The Association paused funding programs in March 2020 after hearing significant challenges from potential applicants in submitting their necessary documents for consideration as a result of the COVID-19 pandemic. The Association continues to be in touch with multi